Legal cannabis expansion prioritizes profit-driven innovation over patient health and public welfare, revealing systemic failures in regulatory oversight

Indigenous and traditional systems (e.g., Ayurveda, Rastafari, African herbalism) have long recognized cannabis’s therapeutic and spiritual roles, but these are systematically excluded from legal frameworks that prioritize Western pharmaceutical models. Corporate legalization often severs cannabis from its cultural roots, reducing it to a commodity while erasing Indigenous intellectual property and sovereignty over medicinal plants. The erasure of these systems reflects a broader pattern of epistemic violence in global health governance.

The current cannabis legalization wave mirrors historical patterns of drug commodification, such as the 20th-century tobacco industry’s co-optation of public health narratives to sell 'safer' cigarettes. Prohibition-era laws (e.g., U.S. Marihuana Tax Act of 1937) were shaped by racist propaganda and corporate lobbying, and today’s legalization risks repeating these mistakes by centering profit over harm reduction. The medical cannabis movement’s origins in the 1970s–90s AIDS and cancer advocacy show how patient-led models were later sidelined by venture capital.

Cross-culturally, cannabis is treated as both medicine and sacrament, with Indigenous communities in Africa, the Caribbean, and South Asia using it for centuries to address mental health, pain, and spiritual well-being. However, Western legalization often strips these uses of their cultural significance, replacing them with standardized, corporate-produced products that lack traditional wisdom. The global North’s approach to cannabis legalization often ignores the communal and spiritual dimensions that make it effective in non-Western contexts.

Scientific research on cannabis is heavily skewed by funding sources, with 80% of U.S. studies funded by pharmaceutical companies that focus on synthetic cannabinoids (e.g., Epidiolex) rather than whole-plant therapies. The lack of standardized dosing, contamination risks in unregulated markets, and biased study designs (e.g., excluding THC-rich strains) undermine public health guidance. Meanwhile, Indigenous and traditional knowledge systems offer robust, long-term evidence of cannabis’s efficacy that is rarely integrated into clinical trials.

Artistic and spiritual traditions (e.g., reggae music’s celebration of cannabis, Hindu and Buddhist rituals) frame cannabis as a tool for creativity, meditation, and communal healing, challenging its reduction to a recreational or medical commodity. However, legalization often commodifies these cultural expressions, turning sacred practices into marketing tropes for brands like 'High Priestess' or 'Sacred Herb.' The spiritual dimensions of cannabis use—such as its role in shamanic journeys or Rastafari livity—are erased when the plant is treated solely as a consumer product.

Future scenarios for cannabis legalization could either entrench corporate monopolies (e.g., Big Pharma controlling synthetic cannabinoids) or enable decentralized, community-based models that prioritize patient needs. Without structural reforms, legalization may exacerbate health disparities, as low-income patients lack access to high-quality medical cannabis while wealthier users benefit from boutique products. Scenario planning must account for climate change impacts on cannabis cultivation (e.g., water scarcity, pesticide use) and the potential for regenerative agricultural practices.

Marginalized communities—particularly Black, Indigenous, and low-income patients—face barriers to accessing medical cannabis due to cost, legal restrictions, and historical distrust of medical systems. The criminalization of cannabis disproportionately targeted these groups, and legalization has yet to address reparative justice (e.g., expungement of past convictions, equitable licensing for minority-owned businesses). Patient advocates, especially those with chronic illnesses or disabilities, are often excluded from policy discussions dominated by industry lobbyists and regulators.